GlassScriptPhysician profile
Shannon E Oehrle
NPI 1598364952
$4,882.51
in general payments reported to CMS, 2019-2025
43 companies · $806 in 2025
The $806 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,009 · 2023: $1,424 · 2024: $1,643 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.42 |
| Education | $155.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $728.98 | 2022-2025 | Breztri, Airsupra |
| Abbvie INC. | $584.72 | 2022-2025 | |
| Astellas Pharma US INC | $306.17 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $293.69 | 2023-2025 | |
| Lilly USA, LLC | $236.58 | 2022-2024 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $224.25 | 2023-2024 | Descovy |
| Collegium Pharmaceutical, INC. | $210.09 | 2022-2024 | Belbuca |
| Edwards Lifesciences Corporation | $206.61 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $206.28 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Genmab U.S., INC. | $191.09 | 2025 | Tivdak |
| Aimmune Therapeutics, INC. | $149.49 | 2024 | |
| Idorsia Pharmaceuticals US INC | $140.92 | 2023 | Quviviq |
| Organon LLC | $139.72 | 2022-2024 | |
| Alkermes, INC. | $128.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $105.63 | 2023-2024 | Austedo, Austedo Xr |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Oehrle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.